SHAREHOLDER ALERT: Khang & Khang LLP Announces an Ongoing Investigation of Claims against Clovis Oncology, Inc. & Advises Inv...
November 29 2015 - 8:28PM
Business Wire
Khang & Khang LLP announces that it is investigating claims
of potential misrepresentations by Clovis Oncology, Inc. (“Clovis”
or the “Company”) (NASDAQ: CLVS). The investigation focuses on
whether the Company and its officers violated securities laws by
issuing misleading information to investors.
If you purchased shares of Clovis during the Class Period,
please contact Joon M. Khang, Esquire, of Khang & Khang, 18101
Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949)
419-3834, or by email at joon@khanglaw.com.
There has been no class certification in this case. Until
certification occurs, you are not represented by an attorney. You
may choose to take no action and remain a passive class member.
The investigation concerns whether the Company violated Sections
10(b) and 20(a) of the Securities Exchange Act of 1934.
Specifically, the investigation will focus on the Company’s
November 16, 2015, announcement that potential approval of its lung
cancer treatment rociletinib will likely be delayed.
If you wish to learn more about this lawsuit, or if
you have any questions concerning this notice or your rights,
please contact Joon M. Khang, a prominent litigator for almost two
decades, by telephone: (949) 419-3834, or by email at
joon@khanglaw.com.
This press release may constitute Attorney Advertising in some
jurisdictions.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151129005050/en/
KHANG & KHANG LLPJoon M. Khang, Esq.Telephone:
949-419-3834Facsimile: 949-225-4474joon@khanglaw.com
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Apr 2023 to Apr 2024